Novotech has expanded its clinical services with a new office in Johannesburg, South Africa
Novotech, Australia’s largest clinical CRO with offices throughout Asia, has expanded its clinical services with a new office in Johannesburg, South Africa to accommodate increasing sponsor demand for quality clinical research management.
Novotech is an internationally recognized full service CRO known for its experience across 11 countries from Australia and New Zealand through Asia to India, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Hong Kong, and now South Africa.
Together with its partner in China, Novotech now provides biotechnology and pharmaceutical companies access to patients from a population base of over 3 billion people
As a leading regional CRO, Novotech has been actively involved in hundreds of drug development programs for US and EU registration over the past 18 years.
CEO Alek Safarian said the expansion to South Africa followed demand from existing USA-based biotechnology sponsors for whom Novotech was already managing clinical trial programs in the Asia Pacific.
“HIV and TB are serious health challenges in some South African patient populations, while metabolic diseases common in the USA and Australia such as diabetes, heart disease and hypertension are also on the increase.”
“As the leading market for clinical trials in Africa, there are currently over 1700 studies registered on the South African Department of Health online registry,” said Safarian
http://www.sanctr.gov.za/SAClinicalbrnbspTrials/tabid/169/Default.aspx
“This expansion into a new territory for us is in keeping with our broader strategy of covering emerging markets for our clients. We have been managing trials in South Africa for three years through consultants already, and this experience will put us in good stead for this new operation to make a strong contribution to the group.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.